Lung cancer RFA (radiofrequency ablation) results boost shares in Rita Medical
This article was originally published in Clinica
Executive Summary
Shares in US-based Rita Medical Systems soared by nearly 30% last week, after the company reported positive data from a trial of its radiofrequency ablation (RFA) treatment for lung cancer. 18-month survival statistics from the study, presented at the Radiological Society of North America (RSNA), in Chicago, showed the RFA technique to be feasible in 99% of the 106 lung cancer patients who took part in the study.